Biotech Values

[DewDiligence]

Re: ASMB CC

First P2a study designed to prove the concept that CpAMs inhibit the generation of new cccDNA molecules. This study will enroll only e antigen+ patients who have a fully suppressed viral load and will test either ABI-H0731 or placebo in combo with a nuke for 6 months… Company noted in Q&A that only including e antigen+ patients in this study because want to include as many surrogate markers as possible and inclusion of e antigen- patients would remove one [i.e. e-antigen per se].

I listened to the CC and thought it was well done. However, the stated rationale for testing only e-antigen+ patients does not entirely ring true, IMO, insofar as loss of e-antigen doesn't imply that you are making any headway wrt cccDNA.